Generate Biomedicines (NASDAQ:GENB) Upgraded at Zacks Research

Zacks Research upgraded shares of Generate Biomedicines (NASDAQ:GENB) to a hold rating in a research report report published on Wednesday morning,Zacks.com reports.

A number of other equities analysts also recently commented on the company. Cantor Fitzgerald assumed coverage on Generate Biomedicines in a report on Tuesday. They issued an “overweight” rating on the stock. Wall Street Zen raised shares of Generate Biomedicines to a “hold” rating in a research report on Saturday, March 14th. The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $26.00 price target on the stock. Guggenheim assumed coverage on shares of Generate Biomedicines in a research report on Tuesday. They set a “buy” rating and a $30.00 price target on the stock. Finally, Morgan Stanley initiated coverage on shares of Generate Biomedicines in a research note on Tuesday. They set an “overweight” rating and a $20.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Generate Biomedicines currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

Generate Biomedicines Stock Down 11.0%

Shares of Generate Biomedicines stock opened at $11.44 on Wednesday. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.